Full-Time

Technical Program Specialist

Deadline 8/1/27
Genus

Genus

1,001-5,000 employees

Global animal genetics and breeding technology

No salary listed

Mound City, SD, USA

In Person

Travel up to 15% may be required, including international travel.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Microsoft Office
Supply Chain Management
Data Analysis

Get referred to Genus

See people who can refer or advise you

Requirements
  • A bachelor's degree in Animal Science, Agriculture, or a related field, or an equivalent combination of education and experience.
  • A minimum of five years of experience within swine production systems, animal research, agricultural technology, or a related environment.
  • Mechanical aptitude and problem-solving skills.
  • Experience collecting, analyzing, and interpreting production or research data to support operational decisions and project outcomes.
  • Demonstrated problem-solving skills, strong attention to detail, and the ability to manage multiple priorities in a fast-paced environment.
  • Proficiency in Microsoft Office and other relevant software applications, with the ability to learn new technologies and systems.
  • Strong communication and interpersonal skills, with the ability to work independently and collaborate across teams.
  • Ability to travel up to 15%, based on supply chain needs.
  • Ability to attain a passport or other travel documents for international travel.
Responsibilities
  • Ensure reliable operation and data collection from the FIRE feeder systems by submitting accurate repair and maintenance logs.
  • Seek assistance from Osbourne when necessary to support proper feeder function, increase efficiency of problem identification, and enable speedy repairs.
  • Support robust data by ensuring that all animals have a working transponder at all times.
  • Download, validate, and submit FIRE feeder data and reports to the GN leadership team.
  • Support monitoring programs that ensure data collection integrity and contribute to genetic improvement objectives.
  • Assist with placing animals on test, removing animals from test, and conducting evaluations according to established protocols.
  • Monitor test progress and communicate risks, challenges, or missed targets to leadership in a timely manner.
  • Ensure compliance with Standard Operating Procedures, biosecurity requirements, and animal welfare standards.
  • Develop and deliver training, coaching, and technical support to team members as needed.
  • Assist with the implementation and adoption of new technologies and process improvements.
  • Maintain accurate project records and documentation.
  • Collaborate with production, product development, supply chain, and other cross-functional teams to support project goals.
  • Present project updates, findings, and recommendations to stakeholders as appropriate.
  • Provide technical guidance and informal leadership to colleagues and team members.
  • Support facility operations by assisting other departments as needed.

Genus is a global animal-genetics company focused on improving cattle and pig performance through breeding and genetic technologies. It operates two main units, ABS Global for bovine genetics and PIC for porcine genetics, offering breeding animals, reproduction services, and gene-editing and next-generation breeding tools. Its products work by combining genetics, reproductive biology, and data-driven selection to produce healthier herds, higher-quality food, and more efficient production. Genus differentiates itself through its global scale (operations in 30 countries and distribution to over 50 markets), its specialized units for cattle and pigs, and its integration of science with practical farming solutions. Its goal is to sustainably nourish the world by improving animal health, food quality, and the resilience of the global food system, while delivering value to customers and upholding ethical, collaborative values.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Basingstoke, United Kingdom

Founded

1933

Get referred to Genus

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FY26 interim results on 26 February 2026 showed record first-half adjusted operating profit.
  • ABS grew genotyping above 30% on 7 May 2026, signaling commercial momentum.
  • 50 million Sexcel units sold by 25 June 2026 proves global scaling.

What critics are saying

  • PIC China deconsolidation removes reported revenue, and 49% ownership cuts control.
  • Genus still depends on regulators in Mexico, Japan, and China for commercialization.
  • If export markets block gene-edited pork, PRRS commercialization stays stranded indefinitely.

What makes Genus unique

  • Genus owns PIC and ABS, spanning pig and bovine genetics globally.
  • Canada approved PRRS-resistant pigs on 23 January 2026, validating its gene-editing moat.
  • The 31 January 2026 China JV with BCA preserves royalties while de-risking exposure.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Parental Leave

Employee Stock Purchase Plan

Paid Holidays

Paid Vacation

Tuition Reimbursement

Flexible Work Hours

Company News

Associated Press
Jan 23rd, 2026
Canada approves PRRSV-resistant pigs for food and feed to cut farm losses and antibiotic use

Canada has approved genetically engineered pigs resistant to porcine reproductive and respiratory syndrome viruses for use in food and feed. Health Canada and the Canadian Food Inspection Agency completed independent safety assessments following applications from Genus PLC and PIC Canada, concluding the pigs are as safe and nutritious as conventional pork. The approval addresses PRRSV, one of the most devastating virus classes affecting farmed pigs, which causes severe symptoms including breathing problems, fever and stillborn piglets. There are currently no effective treatments available. Genus PLC's PRRSV-resistant pigs are already approved in the US, Brazil, Colombia and the Dominican Republic. However, the company will not sell these pigs in Canada until receiving regulatory authorisation in other key markets. Canada's swine industry generated over $6.3 billion in farm cash receipts in 2024.

TipRanks
Oct 21st, 2024
Genus plc CFO to Retire, Successor Search Underway

Genus plc, a global leader in animal genetics, has announced the upcoming retirement of its Chief Financial Officer, Alison Henriksen, who will leave her role in July 2025 after five years with the company.

PharmiWeb
Sep 7th, 2023
Genus Plc Preliminary Results For The Year Ended 30 June 2023

SOLID PERFORMANCE AND GOOD STRATEGIC PROGRESSWEBCAST AVAILABLE AT 7:01AM GMT, 2.01 ESTLONDON--(BUSINESS WIRE)--Genus (LSE:GNS), a leading global animal genetics company, today announces its preliminary results for the year ended 30 June 2023. The full report has been made available on the investors section of the Genus plc website. The Company will discuss its corporate, operational and financial highlights in a pre-recorded webcast at 7:01 AM GMT, 2.01 EST.Commenting on the performance and outlook, Jorgen Kokke, Chief Executive Officer, said:“The Group achieved a strong operational performance despite ongoing challenging market conditions for producers in several important markets. Revenues grew in all regions and both PIC and ABS delivered profit growth. This also enabled us to deliver record adjusted EBITDA and good cashflow for the Group. Growth in R&D investments, primarily due to the strategically important gene editing work and expansion of PIC’s elite farms, as well as higher interest costs, resulted in adjusted profit before tax consistent with the prior year.“PIC’s performance was particularly impressive, achieving a record adjusted operating profit for the year

MarketWatch
Apr 3rd, 2023
Genus Names Jorgen Kokke as Chief Executive Officer Designate

Genus PLC said Monday that it has appointed Jorgen Kokke as chief executive officer designate, effective from May 2.

PharmiWeb
Sep 8th, 2022
Genus Plc Reports Preliminary Results For The Year Ended 30 June 2022

Continued Strategic Progress in Challenging Markets. Webcast Available at 7:01AM BST, 2.01 EDT